Skip to main content
Premium Trial:

Request an Annual Quote

Diamond Healthcare to Offer AssureRx's PGx Test to Guide Antipsychotic Therapy

Premium

Originally published Sept. 28.

Diamond Healthcare has begun rolling out AssureRx Health's GeneSightRx psychiatric pharmacogenetic test in 10 of its nationwide behavioral health units, the companies announced today. Diamond plans to expand adoption of PGx testing within its 30-state network throughout this year and next.

"We plan to offer this state-of-the-art technology to an increasing number of hospitals in our network and differentiate our behavioral health units in the marketplace by improving patient outcomes, while decreasing the cost of patient care," said Diamond Healthcare CEO George White in a statement.

AssureRx will initially launch GeneSightRx as a laboratory-developed test. According to the company, the test will help doctors select the antidepressant and antipsychotic medication a psychiatric patient is most likely to respond to.

GeneSightRx analyzes five gene variants in order to gauge how well patients respond to psychotropic medications.

AssureRx in March announced the addition of a fifth gene, CYP1A2, to its GeneSightRx panel, which already analyzed CYP2D6, CYP2C19, the serotonin transporter gene SLC6A4, and the serotonin 2A receptor gene 5HTR2A.

Diamond Healthcare is a behavioral health and chemical dependency services company headquartered in Richmond, Va. The company partners with healthcare organizations — from rural hospitals to urban academic medical centers — across the country to provide its services.

According to Richard Shrum, Diamond Healthcare executive VP of operations, the healthcare provider has "already implemented GeneSightRx in a number of [its] sites and expect[s] to accelerate adoption of psychiatric pharmacogenetics in the coming months."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.